Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758966 · ClinicalTrials.gov registry record · Phase 2
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
A Phase 2 study, sponsored by Orexigen Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00758966: Clinical Trial Phase 2 study, sponsored by Orexigen Therapeutics.
NCT00758966 is a Phase 2 study that was terminated before completion, run by Orexigen Therapeutics. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00758966, a Phase 2 study, was terminated before completion, sponsored by Orexigen Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either fluoxetine alone or naltrexone SR alone.
Interventions
- DRUG Fluoxetine 60 mg
- DRUG Naltrexone 32 mg and fluoxetine 60 mg
- DRUG Naltrexone SR 32 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-09 |
| Est. Completion | 2008-12 |
| Phase | Phase 2 |
Why NCT00758966 stopped before completion
NCT00758966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Fluoxetine 60 mg is the first listed.
NCT00758966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00758966 about?
NCT00758966 is a clinical study titled "Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder". The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either fluoxetine alone or naltrexone SR alone.
What is the current status of trial NCT00758966?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-09. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00758966?
The interventions under investigation include: Fluoxetine 60 mg (DRUG), Naltrexone 32 mg and fluoxetine 60 mg (DRUG), Naltrexone SR 32 mg (DRUG).
Who is sponsoring clinical trial NCT00758966?
This trial is sponsored by Orexigen Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00758966's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia